1-(苯并[d][1,3]二氧代-4-基)-N-甲基甲胺 | 110931-73-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 中文名称: 1-(苯并[d][1,3]二氧代-4-基)-N-甲基甲胺
• 英文名称: N-(2,3-Methylenedioxybenzyl)methylamine
• 英文别名: benzo[1,3]dioxol-4-ylmethyl-methylamine；1-(Benzo[d][1,3]dioxol-4-yl)-N-methylmethanamine；1-(1,3-benzodioxol-4-yl)-N-methylmethanamine
• CAS: 110931-73-2
• 化学式: C₉H₁₁NO₂
• 分子量: 165.192
• InChiKey: SBRKQMIPPKZACL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2932999099

反应信息

• 作为反应物：
  描述：

  4-[(4-hydroxyphenyl)thio]butanoic acid 、 1-(苯并[d][1,3]二氧代-4-基)-N-甲基甲胺 生成 N-(1,3-benzodioxol-4-ylmethyl)-4-[(4-hydroxyphenyl)thio]-N-methylbutanamide
  参考文献：
  名称：

  NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS

  摘要：

  本发明涉及新型取代芳基衍生物、其制备过程及其用于抑制病毒复制和治疗病毒性疾病或障碍，如HIV和/或HCV感染的用途。

  公开号：

  US20120022054A1

文献信息

• Pyrimidine derivatives as ghrelin receptor modulators
  申请人：Kosogof Christi

  公开号：US20050070712A1

  公开（公告）日：2005-03-31

  The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by ghrelin including anorexia, cancer cachexia, eating disorders, age-related decline in body composition, weight gain, obesity, and diabetes mellitus.

  本发明涉及式(I)的化合物，或者其治疗上适宜的盐或前药，该化合物的制备、含有该化合物的组合物以及在预防或治疗由生长激素释放素调节的疾病中使用该化合物，包括厌食症、癌症恶病质、进食障碍、与年龄相关的身体组成下降、体重增加、肥胖和糖尿病。
• Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists
  申请人：Kosogof Christi

  公开号：US20050171131A1

  公开（公告）日：2005-08-04

  The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the action of ghrelin receptor, including Prader-Willi syndrome, eating disorder, weight gain, weight-loss maintainance following diet and exercise, obesity, and disorders associated with obesity such as noninsulin dependent diabetes mellitus.

  本发明涉及式(I)的化合物，或其治疗上适用的盐或前药，所述化合物的制备，含有所述化合物的组合物以及在预防或治疗由胃泌素受体调节的疾病中使用所述化合物，包括普拉德-威利综合征、进食障碍、体重增加、饮食和锻炼后体重减轻维持、肥胖，以及与肥胖相关的疾病，如非胰岛素依赖型糖尿病。
• Formal synthesis of chelamidine alkaloids and their derivatives
  作者：Rui-Qi Li、Yu He、Yao Ding、Chee-Kiat Ang、Jie-Sheng Tian、Teck-Peng Loh

  DOI：10.1039/c7cc09875h

  日期：——

  broad substrate scope and good tolerance to a variety of substituents such as different aromatic heterocyclic rings. In addition, the effectiveness of this protocol was also demonstrated in the formal synthesis of homochelidonine and chelamidine.

  开发了一个简单的两步醛化α-胺化操作和随后的Friedel-Crafts / Prins型环化反应，以接近四氢苯并[ c ]菲啶和相关结构。该反应显示出广泛的底物范围和对各种取代基如不同的芳族杂环的良好耐受性。此外，该方法的有效性也已在高白屈菜碱和氯胺定的正式合成中得到了证明。
• Compositions comprising multiple bioactive agents, and methods of using the same
  申请人：Berman M. Judd

  公开号：US20060142265A1

  公开（公告）日：2006-06-29

  In part, the present invention is directed to compositions comprising a FabI inhibitor and at least one other bioactive agent. In another part, the present invention is directed to antibacterial compositions comprising a compound of formulas I-III and at least one other antibacterial agent.

  本发明的一部分涉及含有FabI抑制剂和至少一种其他生物活性剂的组合物。另一部分，本发明涉及含有I-III式化合物和至少一种其他抗菌剂的抗菌组合物。
• Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists
  申请人：Xin Zhili

  公开号：US20050171132A1

  公开（公告）日：2005-08-04

  The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the action of ghrelin receptor, including Prader-Willi syndrome, eating disorder, weight gain, weight-loss maintainance following diet and exercise, obesity and disorders associated with obesity such as non-insulin dependent diabetes mellitus.

  本发明涉及式（I）的化合物，或其治疗上适宜的盐或前药，以及该化合物的制备、含有该化合物的组合物以及在预防或治疗由胃饥饿素受体调节的疾病中使用该化合物，包括普拉德-威利综合症、进食障碍、体重增加、饮食和运动后体重减轻维持、肥胖症以及与肥胖症相关的疾病，如非胰岛素依赖性糖尿病。